Sleep Software Market Expected To Reach $1.8 Billion By 2030: Sleep Software Revolutionizing Diagnosis And Management Of Sleep Disorders

(MENAFN- GlobeNewsWire - Nasdaq) The primary market opportunities within the sleep software sector hinge on the growing need for advanced diagnostic tools in managing sleep disorders, coupled with the rise in wearable tech integration

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Sleep Software Market" has been added to ResearchAndMarkets's offering.

The global sleep software market, valued at $1.1 billion in 2025, is forecasted to ascend to $1.8 billion by 2030, asserting a compound annual growth rate (CAGR) of 11.4% during this period. Sleep software is an essential technological advancement aiding clinicians and researchers in diagnosing, managing, and comprehensively understanding sleep disorders. It accomplishes this by collecting, analyzing, and interpreting data from various sleep studies, including polysomnography (PSG), home sleep tests, and wearable devices.

The software effectively translates raw physiological signals-comprised of brain activity, breathing patterns, oxygen levels, and heart rate-into insightful data, thus significantly refining the precision and efficacy of sleep assessments. Some of the market's key players include Calm, ResMed, Koninklijke Philips N.V., Inspire Medical Systems Inc., and Fisher & Paykel Healthcare Limited. In this competitive domain, innovation through software upgrades and enhanced features are paramount to sustain user engagement and ensure continued clinical reliability and profitability.

Report Scope

This comprehensive report serves as a vital tool for businesses assessing technologies, trends, products, and key players in the cannabis sector. It encompasses critical market segments like cannabis analytical testing equipment and services, cannabis extraction equipment, and services, alongside legal cannabis retail sales for medicinal and adult use, and cannabis-derived pharmaceuticals. BCC Research provides market data for 2024 as the base year, along with 2025 estimates, and forecasts up to 2030.

Importantly, this report excludes illegal cannabis, industrial hemp, and cannabis grown for personal consumption. It is pertinent to highlight that the retail sales statistics focus solely on domestic medical and adult-use cannabis sales, omitting the export market.

The report includes:

• 43 data tables and 40 additional tables.
• Comprehensive analysis of the global oligonucleotides market.
• Insights into global market trends with historical sales data from 2022 to 2024, projections for 2025, and CAGRs through 2030.
• Current market size and revenue outlook for the global oligonucleotide synthesis market, presented by product, application, and regional market share.
• Thorough exploration of global market dynamics, opportunities and challenges, technological advancements, regulatory impacts, and macroeconomic factors.
• Insights from Porter's Five Forces model and global supply chain analyses.
• Patent reviews highlighting key granted and published patents.
• Analysis of industry structure including market shares, product mapping, strategic moves, M&A activities, and venture funding prospects.
• Overview of sustainability trends and ESG developments, focusing on consumer attitudes, and evaluating ESG risk ratings and practices of leading companies.
• Profiles of major industry players, including ResMed, Koninklijke Philips N.V., Inspire Medical Systems Inc., Fisher & Paykel Healthcare Limited, Calm, Cadwell Industries Inc., Compumedics Ltd., Headspace Inc., Natus, and Nihon Kohden Corp.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN20022026004107003653ID1110767782